Tebanicline

Tebanicline

SCHEMBL677444

Clc1ccc(OC[C@@H]2CCN2)cn1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

CHRNA4CHRNB2

The experimentally established mechanism targets of Tebanicline. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 6)

geneUniProtsupporting neighboursconfidence
CHRNB2 known ✓ P17787 3/20 1.00
CHRNA4 known ✓ P43681 3/20 1.00
CHRNA3 P32297 4/20 1.00
CHRNB4 P30926 2/20 1.00
CHRNA7 P36544 1/20 1.00
CYP2D6 P10635 2/20 0.62

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Tebanicline SCHEMBL120178 1.00 CHRNA3 (1.00) CHRNA3CHRNB2CHRNA4CHRNB4CHRNA7
Tebanicline SCHEMBL29711092 1.00 CHRNA3 (1.00) CHRNA3CHRNB2CHRNA4CHRNB4CHRNA7
Tebanicline SCHEMBL120179 1.00 CHRNA3 (1.00) CHRNA3CHRNB2CHRNA4CHRNB4CHRNA7
Tebanicline SCHEMBL15663029 0.98 CHRNA3 (0.97) CHRNA3CHRNB2CHRNA4CHRNB4CHRNA7
Tebanicline SCHEMBL15663031 0.98 CHRNA3 (0.97) CHRNA3CHRNB2CHRNA4CHRNB4CHRNA7
Tebanicline SCHEMBL7407195 0.98 CHRNA3 (0.97) CHRNA3CHRNB2CHRNA4CHRNB4CHRNA7
SCHEMBL905233 0.89 CHRNA3 (1.00) CHRNA3CHRNB2CHRNA4CHRNB4CHRNA7
SCHEMBL8440116 0.89 CHRNA3 (1.00) CHRNA3CHRNB2CHRNA4CHRNB4CHRNA7
Hydrochloric Acid SCHEMBL8437569 0.88 CHRNA3 (0.97) CHRNA3CHRNB2CHRNA4CHRNB4CHRNA7
Hydrochloric Acid SCHEMBL8435785 0.88 CHRNA3 (0.97) CHRNA3CHRNB2CHRNA4CHRNB4CHRNA7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1434573-A2 IRRIGATION SOLUTION AND METHOD FOR INHIBITION OF PAIN AND INFLAMMATION Omeros Corporation (US) 2004-07-07 EP claimed
US-20020028798-A1 Irrigation solution and method for inhibition of pain and inflammation OMEROS MEDICAL SYSTEMS 2002-03-07 US claimed
WO-2000023062-A2 IRRIGATION SOLUTION AND METHOD FOR INHIBITION OF PAIN AND INFLAMMATION OMEROS MEDICAL SYSTEMS, INC. (US) 2000-04-27 WO claimed
US-6054451-A THE EFFECTIVENESS OF (R) OR (S) 5-(2-AZETIDINYLMETHOXY)-2-CHLOROPYRIDINE, IS SIGNIFICANTLY POTENTIATED BY ADMINISTERING AN ANALGESIC-POTENTIATING AMOUNT FOR SAID ANALGESIC OF AT LEAST ONE NONTOXIC NMDA RECEPTOR ALGOS PHARMACEUTICAL CORPORATION (US) 2000-04-25 US claimed
WO-1999053922-A1 ANALGESIC COMPOSITIONS COMPRISING NMDA-ANTAGONISTS AND ABT-594 ALGOS PHARMACEUTICAL CORPORATION (US) 1999-10-28 WO claimed
US-5948793-A 3-pyridyloxymethyl heterocyclic ether compounds useful in controlling neurotransmitter release ABBOTT LABORATORIES (US) 1999-09-07 US claimed
US-20220062252-A1 CYCLOOXYGENASE INHIBITOR AND CALCIUM CHANNEL ANTAGONIST COMPOSITIONS AND METHODS FOR USE IN UROLOGICAL PROCEDURES OMEROS CORP (US) 2022-03-03 US disclosed
US-20210290605-A1 CYCLOOXYGENASE INHIBITOR AND CALCIUM CHANNEL ANTAGONIST COMPOSITIONS AND METHODS FOR USE IN UROLOGICAL PROCEDURES OMEROS CORP (US) 2021-09-23 US disclosed
US-20190083477-A1 Cyclooxygenase Inhibitor and Calcium Channel Antagonist Compositions and Methods for Use in Urological Procedures OMEROS CORP (US) 2019-03-21 US disclosed
US-9855256-B2 Cyclooxygenase inhibitor and calcium channel antagonist compositions and methods for use in urological procedures OMEROS CORPORATION (US) 2018-01-02 US disclosed
US-20170246150-A1 Arthroscopic irrigation solution and method for peripheral vasoconstriction and inhibition of pain and inflammation OMEROS CORPORATION 2017-08-31 US disclosed
US-20170182007-A1 Arthroscopic Irrigation Solution and Method for Peripheral Vasoconstriction and Inhibition of Pain and Inflammation OMEROS CORPORATION 2017-06-29 US disclosed
EP-1881821-B1 COMPOSITIONS COMPRISING KETOPROFEN AND CALCIUM CHANNEL ANTAGONIST FOR USE IN UROLOGICAL PROCEDURES OMEROS CORP (US) 2016-11-09 EP disclosed
WO-2000023062-A2 IRRIGATION SOLUTION AND METHOD FOR INHIBITION OF PAIN AND INFLAMMATION OMEROS MEDICAL SYSTEMS, INC. (US) 2000-04-27 WO disclosed
US-6054451-A THE EFFECTIVENESS OF (R) OR (S) 5-(2-AZETIDINYLMETHOXY)-2-CHLOROPYRIDINE, IS SIGNIFICANTLY POTENTIATED BY ADMINISTERING AN ANALGESIC-POTENTIATING AMOUNT FOR SAID ANALGESIC OF AT LEAST ONE NONTOXIC NMDA RECEPTOR ALGOS PHARMACEUTICAL CORPORATION (US) 2000-04-25 US disclosed
US-6054451-A THE EFFECTIVENESS OF (R) OR (S) 5-(2-AZETIDINYLMETHOXY)-2-CHLOROPYRIDINE, IS SIGNIFICANTLY POTENTIATED BY ADMINISTERING AN ANALGESIC-POTENTIATING AMOUNT FOR SAID ANALGESIC OF AT LEAST ONE NONTOXIC NMDA RECEPTOR ALGOS PHARMACEUTICAL CORPORATION (US) 2000-04-25 US disclosed
WO-1999064038-A1 NOVEL ANALGESIC AGENTS ADVANCED MEDICINE, INC. (US) 1999-12-16 WO disclosed
WO-1999053922-A1 ANALGESIC COMPOSITIONS COMPRISING NMDA-ANTAGONISTS AND ABT-594 ALGOS PHARMACEUTICAL CORPORATION (US) 1999-10-28 WO disclosed
WO-1999053922-A1 ANALGESIC COMPOSITIONS COMPRISING NMDA-ANTAGONISTS AND ABT-594 ALGOS PHARMACEUTICAL CORPORATION (US) 1999-10-28 WO disclosed
US-5948793-A 3-pyridyloxymethyl heterocyclic ether compounds useful in controlling neurotransmitter release ABBOTT LABORATORIES (US) 1999-09-07 US disclosed